Home » Newsletters » BioWorld Science

BioWorld Science

May 3, 2012

View Archived Issues

New phase III results reported on Biogen Idec drug for MS

CO-releasing compound protects against cerebral malaria

Multikinase inhibitor from Piramal Life Sciences significantly suppresses tumor growth

New vasopressin V1B receptor antagonists designed in Japan

Boehringer Ingelheim Pharma develops new CD33-binding antibodies

Novel candidate cancer immunotherapies presented by Oxford BioTherapeutics

Amrita Therapeutics divulges new potential cancer therapies

Second-generation cyclophilin inhibitor selected for clinical development in hepatitis C

Study in Chinese children links LINE-1 methylation to congenital heart defect

Advanced Cell Technology confirms additional site for dry AMD stem cell trial

AVEO reports preliminary data from phase II ficlatuzumab combination trial

Zogenix submits NDA for Zohydro

BioAnalytica discloses novel HSP 90-targeting antibodies

Trevena enters collaboration to identify novel biased ligand molecules

Altor BioScience product to enter clinical testing for melanoma

Kyowa Hakko Kirin offers development update for first quarter 2012

Cleveland BioLabs and Incuron receive clearance for CBLC-137 trial in Russia

Quark to conduct phase IIa study of siRNA drug in open-angle glaucoma

Enrollment complete in pivotal study of oral testosterone replacement therapy

Ultragenyx reports first-in-human data on UX-001

SUMMACTA study meets primary endpoint

Genomic Health and OncoMed form alliance

Dako and Genentech to collaborate on U.S. regulatory submissions for companion diagnostics

Azelon completes phase II study of nasal spray for osteoporosis

Janssen seeks approval of Xarelto for additional indications

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...